Pathways for aberrant angiogenesis in pancreatic cancer

Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease. Althoughthe specific mechanisms that dictate its biological aggressiveness are notclearly established, it is characterized by a variety of molecularalterations as well as by the overexpression of mitogenic and angiogenicgrowth factors and their receptors. PDACs also express high levels ofvascular endothelial growth factor (VEGF). Recent studies indicate thatsuppression of VEGF expression attenuates pancreatic cancer celltumorigenicity in a nude mouse model, and that VEGF can exert directmitogenic effects on some pancreatic cancer cells. These findings suggestthat cancer cell derived VEGF promotes pancreatic cancer growth in vivo viaa paracrine angiogenic pathway and an autocrine mitogenic pathway, andprovide novel opportunities for therapeutic intervention in this deadlydisease.

[1]  L. Ellis,et al.  Inhibition of growth and metastasis of human pancreatic cancer growing in nude mice by PTK 787/ZK222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases. , 2001, Cancer biotherapy & radiopharmaceuticals.

[2]  I. Fidler,et al.  Constitutive and inducible interleukin 8 expression by hypoxia and acidosis renders human pancreatic cancer cells more tumorigenic and metastatic. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[3]  J. Massagué.  TGF-beta signal transduction. , 1998, Annual review of biochemistry.

[4]  S. Post,et al.  High Expression of Vascular Endothelial Growth Factor Predicts Early Recurrence and Poor Prognosis after Curative Resection for Ductal Adenocarcinoma of the Pancreas , 2002, Pancreas.

[5]  N. Ferrara,et al.  VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism , 2002, Nature.

[6]  Lieve Moons,et al.  Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele , 1996, Nature.

[7]  H. Friess,et al.  Induction of platelet‐derived growth factor A and B chains and over‐expression of their receptors in human pancreatic cancer , 1995, International journal of cancer.

[8]  H. Buhr,et al.  Angiogenesis inhibitor TNP-470 reduces human pancreatic cancer growth , 2001, Journal of Gastrointestinal Surgery.

[9]  H. Friess,et al.  Increased expression of keratinocyte growth factor in human pancreatic cancer. , 1995, Biochemical and biophysical research communications.

[10]  H. Friess,et al.  Amphiregulin is a potent mitogen in human pancreatic-cancer cells - correlation with patient survival. , 1995, International journal of oncology.

[11]  M. Bryer,et al.  Treatment of resectable and locally advanced pancreatic cancer. , 2000, Cancer control : journal of the Moffitt Cancer Center.

[12]  M. Moses,et al.  HIF-1alpha-mediated up-regulation of vascular endothelial growth factor, independent of basic fibroblast growth factor, is important in the switch to the angiogenic phenotype during early tumorigenesis. , 2001, Cancer research.

[13]  M. Korc,et al.  Insulin-like growth factor I overexpression in human pancreatic cancer: evidence for autocrine and paracrine roles. , 1995, Cancer research.

[14]  H. Friess,et al.  Aberrant expression of type I fibroblast growth factor receptor in human pancreatic adenocarcinomas. , 1993, Cancer research.

[15]  D. Hicklin,et al.  Epidermal growth factor receptor blockade by antibody IMC‐C225 inhibits growth of a human pancreatic carcinoma xenograft in nude mice , 2000, Cancer.

[16]  H. Friess,et al.  Coexpression of the c-met proto-oncogene and hepatocyte growth factor in human pancreatic cancer. , 1994, Cancer research.

[17]  D. Hicklin,et al.  Effect of p53 Status on Tumor Response to Antiangiogenic Therapy , 2002, Science.

[18]  H. Friess,et al.  Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma. , 1997, British Journal of Cancer.

[19]  R. L. Baldwin,et al.  Enhanced expression of the type II transforming growth factor beta receptor in human pancreatic cancer cells without alteration of type III receptor expression. , 1993, Cancer research.

[20]  H. Hamada,et al.  Gene Therapy for Pancreatic Cancer Using an Adenovirus Vector Encoding Soluble flt-1 Vascular Endothelial Growth Factor Receptor , 2002, Pancreas.

[21]  Masato Nakamura,et al.  Ribozyme mediated cleavage of cell-associated isoform of vascular endothelial growth factor inhibits liver metastasis of a pancreatic cancer cell line. , 2002, International journal of oncology.

[22]  S. Kern.  Molecular genetic alterations in ductal pancreatic adenocarcinomas. , 2000, The Medical clinics of North America.

[23]  Shigeyoshi Itohara,et al.  Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis , 2000, Nature Cell Biology.

[24]  Helmut Friess,et al.  VEGF-RII Influences the Prognosis of Pancreatic Cancer , 2002, Annals of surgery.

[25]  K. Alitalo,et al.  A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. , 1996, The EMBO journal.

[26]  I. Fidler,et al.  Angiogenesis and cancer metastasis: antiangiogenic therapy of human pancreatic adenocarcinoma , 2001, International Journal of Clinical Oncology.

[27]  Donald W Kufe,et al.  Vascular Endothelial Growth Factor Enhances Endothelial Cell Survival and Tumor Radioresistance , 2002, Cancer journal.

[28]  A. Nakao,et al.  Expression of plasminogen activators and their inhibitors in human pancreatic carcinoma: immunohistochemical study. , 1993, The American journal of gastroenterology.

[29]  J. Abbruzzese,et al.  Molecular regulation of constitutive expression of interleukin-8 in human pancreatic adenocarcinoma. , 2000, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[30]  K. Alitalo,et al.  VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development. , 1996, Development.

[31]  H. Dvorak,et al.  Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis. , 1999, Current topics in microbiology and immunology.

[32]  H. Friess,et al.  Enhanced expression of the type II transforming growth factor-beta receptor is associated with decreased survival in human pancreatic cancer. , 1999, Pancreas.

[33]  P. Pollock,et al.  Cloning and characterization of a novel human gene related to vascular endothelial growth factor. , 1996, Genome research.

[34]  A. Gown,et al.  A peptide derived from the non-receptor-binding region of urokinase plasminogen activator inhibits glioblastoma growth and angiogenesis in vivo in combination with cisplatin. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[35]  J. Folkman.  What is the evidence that tumors are angiogenesis dependent? , 1990, Journal of the National Cancer Institute.

[36]  Georg Breier,et al.  Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo , 1992, Nature.

[37]  J. Folkman.  Angiogenesis in cancer, vascular, rheumatoid and other disease , 1995, Nature Medicine.

[38]  M. Korc,et al.  Role of growth factors in pancreatic cancer. , 1998, Surgical oncology clinics of North America.

[39]  H. Friess,et al.  Presence of Two Signaling TGF-β Receptors in Human Pancreatic Cancer Correlates with Advanced Tumor Stage , 1997, Digestive Diseases and Sciences.

[40]  M. Korc,et al.  Soluble type II transforming growth factor-beta receptor attenuates expression of metastasis-associated genes and suppresses pancreatic cancer cell metastasis. , 2002, Molecular cancer therapeutics.

[41]  H. Friess,et al.  Detection and localization of MIP‐3α/LARC/exodus, a macrophage proinflammatory chemokine, and its CCR6 receptor in human pancreatic cancer , 1999 .

[42]  R. Crystal,et al.  Regional suppression of tumor growth by in vivo transfer of a cDNA encoding a secreted form of the extracellular domain of the flt-1 vascular endothelial growth factor receptor. , 1998, Human gene therapy.

[43]  M. Korc,et al.  Concomitant over‐expression of vascular endothelial growth factor and its receptors in pancreatic cancer , 2000, International journal of cancer.

[44]  D. Rifkin,et al.  Requirement for transglutaminase in the activation of latent transforming growth factor-beta in bovine endothelial cells , 1993, The Journal of cell biology.

[45]  M. Korc,et al.  Soluble Type II Transforming Growth Factor-β (TGF-β) Receptor Inhibits TGF-β Signaling in COLO-357 Pancreatic Cancer Cells in Vitro and Attenuates Tumor Formation , 2001 .

[46]  T. Veikkola,et al.  Regulation of angiogenesis via vascular endothelial growth factor receptors. , 2000, Cancer research.

[47]  D. Rifkin,et al.  Latent transforming growth factor-beta: structural features and mechanisms of activation. , 1997, Kidney international.

[48]  K. Pumiglia,et al.  Vascular Endothelial Growth Factor Induction of the Angiogenic Phenotype Requires Ras Activation* , 2001, The Journal of Biological Chemistry.

[49]  Shay Soker,et al.  Neuropilin-1 Is Expressed by Endothelial and Tumor Cells as an Isoform-Specific Receptor for Vascular Endothelial Growth Factor , 1998, Cell.

[50]  M. Dewhirst,et al.  Tissue transglutaminase is expressed, active, and directly involved in rat dermal wound healing and angiogenesis , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[51]  P. Meltzer,et al.  Enhanced expression of epidermal growth factor receptor correlates with alterations of chromosome 7 in human pancreatic cancer. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[52]  M. Yashiro,et al.  Enhanced VEGF production and decreased immunogenicity induced by TGF-β 1 promote liver metastasis of pancreatic cancer , 2001, British Journal of Cancer.

[53]  G. Parham,et al.  Secretion of vascular endothelial growth factor in ovarian cancer. , 1999, European journal of gynaecological oncology.

[54]  L. Ellis,et al.  Blockade of insulin-like growth factor I receptor function inhibits growth and angiogenesis of colon cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[55]  A. Wilks,et al.  Inhibition of growth of C6 glioma cells in vivo by expression of antisense vascular endothelial growth factor sequence. , 1996, Cancer research.

[56]  T. Kitsukawa,et al.  Overexpression of a membrane protein, neuropilin, in chimeric mice causes anomalies in the cardiovascular system, nervous system and limbs. , 1995, Development.

[57]  G. Neufeld,et al.  Vascular endothelial growth factor (VEGF) and its receptors , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[58]  D. Hanahan,et al.  Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis , 1996, Cell.

[59]  Vascular endothelial growth factor is increased in ascites from metastatic pancreatic cancer. , 2002, The Journal of surgical research.

[60]  H. Friess,et al.  Induction and expression of heparin-binding EGF-like growth factor in human pancreatic cancer. , 1994, Biochemical and biophysical research communications.

[61]  J. Kleeff,et al.  Transfection of the type I TGF‐β receptor restores TGF‐β responsiveness in pancreatic cancer , 1998 .

[62]  H. Friess,et al.  Growth Factors in Pancreatic Health and Disease , 2001, Pancreatology.

[63]  J. Abbruzzese,et al.  Constitutive Sp1 activity is essential for differential constitutive expression of vascular endothelial growth factor in human pancreatic adenocarcinoma. , 2001, Cancer research.

[64]  L. Ellis,et al.  Impact of Insulin-Like Growth Factor Receptor-I Function on Angiogenesis, Growth, and Metastasis of Colon Cancer , 2002, Laboratory Investigation.

[65]  A. Harris,et al.  Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3'-kinase/Akt signaling pathway. , 2001, Cancer research.

[66]  O. Volpert,et al.  Smad4/DPC4-mediated tumor suppression through suppression of angiogenesis. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[67]  J. Kleeff,et al.  Up-regulation of transforming growth factor (TGF)-beta receptors by TGF-beta1 in COLO-357 cells. , 1998, The Journal of biological chemistry.

[68]  Kusum Joshi,et al.  Angiogenesis as an independent prognostic indicator in node-negative breast cancer. , 2002, Analytical and quantitative cytology and histology.

[69]  M. Korc,et al.  Fibroblast growth factor-5 stimulates mitogenic signaling and is overexpressed in human pancreatic cancer: evidence for autocrine and paracrine actions , 1997, Oncogene.

[70]  M. Kuwano,et al.  ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase. , 2002, Cancer research.

[71]  R. Kerbel,et al.  Impact of oncogenes in tumor angiogenesis: mutant K-ras up-regulation of vascular endothelial growth factor/vascular permeability factor is necessary, but not sufficient for tumorigenicity of human colorectal carcinoma cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[72]  Overexpression of Lymphangiogenic Growth Factor VEGF-C in Human Pancreatic Cancer , 2001, Pancreas.

[73]  H. Friess,et al.  Overexpression of Smad2 and Colocalization with TGF-β1 in Human Pancreatic Cancer , 1999, Digestive Diseases and Sciences.

[74]  C. Van Waes,et al.  Effects of pharmacologic antagonists of epidermal growth factor receptor, PI3K and MEK signal kinases on NF‐κB and AP‐1 activation and IL‐8 and VEGF expression in human head and neck squamous cell carcinoma lines , 2002, International journal of cancer.

[75]  J. Rossant,et al.  Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium , 1995, Nature.

[76]  J. Kleeff,et al.  Up-regulation of Transforming Growth Factor (TGF)-β Receptors by TGF-β1 in COLO-357 Cells* , 1998, The Journal of Biological Chemistry.

[77]  R. Johnson,et al.  Angiogenesis: the role of the microenvironment in flipping the switch. , 2001, Current opinion in genetics & development.

[78]  H. Friess,et al.  Enhanced expression of vascular endothelial growth factor in human pancreatic cancer correlates with local disease progression. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[79]  Kenneth J. Hillan,et al.  Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene , 1996, Nature.

[80]  H. Augustin,et al.  A novel vascular endothelial growth factor encoded by Orf virus, VEGF‐E, mediates angiogenesis via signalling through VEGFR‐2 (KDR) but not VEGFR‐1 (Flt‐1) receptor tyrosine kinases , 1999, The EMBO journal.

[81]  M. Korc,et al.  Production of transforming growth factor alpha in human pancreatic cancer cells: evidence for a superagonist autocrine cycle. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[82]  M. Korc,et al.  Inhibition of basal and mitogen-stimulated pancreatic cancer cell growth by cyclin D1 antisense is associated with loss of tumorigenicity and potentiation of cytotoxicity to cisplatinum. , 1998, The Journal of clinical investigation.

[83]  Lei Xu,et al.  Pancreas Microenvironment Promotes VEGF Expression and Tumor Growth: Novel Window Models for Pancreatic Tumor Angiogenesis and Microcirculation , 2001, Laboratory Investigation.

[84]  J. Rakic,et al.  Influence of plasminogen activator inhibitor type 1 on choroidal neovascularization. , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[85]  H. Friess,et al.  Detection and localization of Mip-3alpha/LARC/Exodus, a macrophage proinflammatory chemokine, and its CCR6 receptor in human pancreatic cancer. , 1999, International journal of cancer.

[86]  M. Korc,et al.  Increased expression of insulin receptor substrate-1 in human pancreatic cancer. , 1996, Biochemical and biophysical research communications.

[87]  H. Friess,et al.  Enhanced expression of transforming growth factor β isoforms in pancreatic cancer correlates with decreased survival , 1993 .

[88]  B. Wiedenmann,et al.  De novo expression of vascular endothelial growth factor in human pancreatic cancer: evidence for an autocrine mitogenic loop. , 2000, Gastroenterology.

[89]  C. Palmer,et al.  Brain edema in meningiomas is associated with increased vascular endothelial growth factor expression. , 1997, Neurosurgery.

[90]  Y. A. Minamishima,et al.  Tumor suppression through angiogenesis inhibition by SUIT-2 pancreatic cancer cells genetically engineered to secrete NK4. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[91]  H. Elsässer,et al.  Characterization of a transglutaminase expressed in human pancreatic adenocarcinoma cells. , 1993, European journal of cell biology.

[92]  K. Alitalo,et al.  Vascular endothelial growth factor B, a novel growth factor for endothelial cells. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[93]  K.,et al.  Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[94]  Bing Li,et al.  Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo , 1993, Nature.

[95]  T. Fukuda,et al.  High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma , 2000, Cancer.

[96]  W. Cavenee,et al.  Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[97]  P. Andreasen,et al.  The plasminogen activation system in tumor growth, invasion, and metastasis , 2000, Cellular and Molecular Life Sciences CMLS.

[98]  L. Ossowski,et al.  EGFR is a transducer of the urokinase receptor initiated signal that is required for in vivo growth of a human carcinoma. , 2002, Cancer cell.

[99]  L. Ellis,et al.  Vessel counts and vascular endothelial growth factor expression in pancreatic adenocarcinoma. , 1998, European journal of cancer.

[100]  M. Korc,et al.  Role of Fibroblast Growth Factors and Their Receptors in Pancreatic Cancer and Chronic Pancreatitis , 1998, Pancreas.

[101]  P. Wingo,et al.  Cancer statistics, 1997 , 1997, CA: a cancer journal for clinicians.

[102]  H. Friess,et al.  Bone morphogenetic protein 2 exerts diverse effects on cell growth in vitro and is expressed in human pancreatic cancer in vivo. , 1999, Gastroenterology.

[103]  H. Moses,et al.  Transforming growth factor beta 1-induced changes in cell migration, proliferation, and angiogenesis in the chicken chorioallantoic membrane , 1990, The Journal of cell biology.

[104]  N. Ferrara.  Molecular and biological properties of vascular endothelial growth factor , 1999, Journal of Molecular Medicine.

[105]  K. Alitalo,et al.  A novel vascular endothelial growth factor, VEGF‐C, is a ligand for the Flt4 (VEGFR‐3) and KDR (VEGFR‐2) receptor tyrosine kinases. , 1996, The EMBO journal.

[106]  S. Grimm,et al.  Antitumor and antimetastatic activity of ribozymes targeting the messenger RNA of vascular endothelial growth factor receptors. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[107]  J. Park,et al.  The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. , 1993, Molecular biology of the cell.

[108]  R. Abrams.  Role of radiation therapy in the management of the patient with pancreatic cancer. , 1996, Oncology.

[109]  I. Fidler,et al.  Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. , 2000, Cancer research.

[110]  H. Friess,et al.  Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness. , 1993, Anticancer research.

[111]  H. Friess,et al.  Synthesis and expression of transforming growth factor beta-1, beta-2, and beta-3 in the endocrine and exocrine pancreas. , 1993, Diabetes.

[112]  A. Abioye,et al.  Pancreatic carcinoma. , 2020, Journal of the National Medical Association.

[113]  H. Friess,et al.  Enhanced erbB-3 expression in human pancreatic cancer correlates with tumor progression. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[114]  G. Sledge.  Vascular endothelial growth factor in breast cancer: biologic and therapeutic aspects. , 2002, Seminars in oncology.

[115]  Janet Rossant,et al.  Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice , 1995, Nature.

[116]  H. Friess,et al.  Induction and expression of amphiregulin in human pancreatic cancer. , 1994, Cancer research.

[117]  A. Ullrich,et al.  SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. , 1999, Cancer research.

[118]  M. Adachi,et al.  Prognostic significance of angiogenesis in human pancreatic cancer , 1999, British Journal of Cancer.

[119]  H. Friess,et al.  Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transforming growth factor alpha. , 1992, The Journal of clinical investigation.

[120]  R. D'Amato,et al.  Persistence of microscopic human cancers in mice: alterations in the angiogenic balance accompanies loss of tumor dormancy , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[121]  H. Friess,et al.  Overexpression of HER2/neu oncogene in human pancreatic carcinoma. , 1993, Human pathology.

[122]  M. Korc,et al.  Altered Expression of Insulin‐like Growth Factor II Receptor in Human Pancreatic Cancer , 1997, Pancreas.

[123]  A. Ullrich,et al.  Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant , 1994, Nature.

[124]  G. Neufeld,et al.  VEGF145, a Secreted Vascular Endothelial Growth Factor Isoform That Binds to Extracellular Matrix* , 1997, The Journal of Biological Chemistry.

[125]  Michael P. Myers,et al.  PTEN controls tumor-induced angiogenesis , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[126]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[127]  M. Korc,et al.  Suppression of fibroblast growth factor receptor signaling inhibits pancreatic cancer growth in vitro and in vivo. , 1998, Gastroenterology.

[128]  H. Friess,et al.  Cripto, a member of the epidermal growth factor family, is over‐expressed in human pancreatic cancer and chronic pancreatitis , 1994, International journal of cancer.

[129]  T. Kitsukawa,et al.  Targeting of both mouse neuropilin-1 and neuropilin-2 genes severely impairs developmental yolk sac and embryonic angiogenesis , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[130]  J. Kleeff,et al.  Transfection of the type I TGF-beta receptor restores TGF-beta responsiveness in pancreatic cancer. , 1998, International journal of cancer.

[131]  H. Buhr,et al.  Specific targeting of tumor vasculature by diphtheria toxin-vascular endothelial growth factor fusion protein reduces angiogenesis and growth of pancreatic cancer , 2002, Journal of Gastrointestinal Surgery.

[132]  H. Hutchings,et al.  Signal relays in the VEGF system. , 1999, Frontiers in bioscience : a journal and virtual library.

[133]  H. Friess,et al.  Overexpression of acidic and basic fibroblast growth factors in human pancreatic cancer correlates with advanced tumor stage. , 1993, Cancer research.

[134]  G. Neufeld,et al.  Neuropilin-2 and Neuropilin-1 Are Receptors for the 165-Amino Acid Form of Vascular Endothelial Growth Factor (VEGF) and of Placenta Growth Factor-2, but Only Neuropilin-2 Functions as a Receptor for the 145-Amino Acid Form of VEGF* , 2000, The Journal of Biological Chemistry.

[135]  M. Korc,et al.  Pancreatic cancer cell‐derived vascular endothelial growth factor is biologically active in vitro and enhances tumorigenicity in vivo , 2001, International journal of cancer.

[136]  Y. Hirata,et al.  Molecular cloning of a novel vascular endothelial growth factor, VEGF-D. , 1997, Genomics.

[137]  H. Friess,et al.  Synthesis and Expression of Transforming Growth Factor β-1, β-2, and β-3 in the Endocrine and Exocrine Pancreas , 1993, Diabetes.

[138]  D. Hicklin,et al.  Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy , 1998, Cancer and Metastasis Reviews.

[139]  S. Kitano,et al.  Anti-tumor angiogenesis therapy using soluble receptors: enhanced inhibition of tumor growth when soluble fibroblast growth factor receptor-1 is used with soluble vascular endothelial growth factor receptor , 2002, Cancer Gene Therapy.

[140]  M. Shibuya.  Structure and function of VEGF/VEGF-receptor system involved in angiogenesis. , 2001, Cell structure and function.

[141]  J. Harmey,et al.  Vascular endothelial growth factor (VEGF), a survival factor for tumour cells: implications for anti-angiogenic therapy. , 2002, BioEssays : news and reviews in molecular, cellular and developmental biology.

[142]  G. Neufeld,et al.  Neuropilin-2 is a receptor for the vascular endothelial growth factor (VEGF) forms VEGF-145 and VEGF-165 [corrected]. , 2000, The Journal of biological chemistry.

[143]  P. Malfertheiner,et al.  Reduced PTEN expression in the pancreas overexpressing transforming growth factor-beta 1 , 2002, British Journal of Cancer.

[144]  J. Winer,et al.  The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. , 1991, Molecular endocrinology.

[145]  G. Viglietto,et al.  Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[146]  M. Büchler,et al.  Expression of a truncated EGF receptor is associated with inhibition of pancreatic cancer cell growth and enhanced sensitivity to cisplatinum , 1996, International journal of cancer.

[147]  M. Korc,et al.  Soluble type II transforming growth factor-beta (TGF-beta) receptor inhibits TGF-beta signaling in COLO-357 pancreatic cancer cells in vitro and attenuates tumor formation. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[148]  S. Rafii,et al.  VEGF(165) promotes survival of leukemic cells by Hsp90-mediated induction of Bcl-2 expression and apoptosis inhibition. , 2002, Blood.

[149]  H. Friess,et al.  Concomitant over‐expression of activin/inhibin β subunits and their receptors in human pancreatic cancer , 1998, International journal of cancer.

[150]  M. Karkkainen,et al.  VEGFR3 gene structure, regulatory region, and sequence polymorphisms. , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.